Annals of internal medicine
-
Comment Randomized Controlled Trial
In migraine with previous treatment failures, eptinezumab safely reduced migraine days at 1 to 12 wk.
Ashina M, Lanteri-Minet M, Pozo-Rosich P, et al. Safety and efficacy of eptinezumab for migraine prevention in patients with two-to-four previous preventive treatment failures (DELIVER): a multi-arm, randomised, double-blind, placebo-controlled, phase 3b trial. Lancet Neurol. 2022;21:597-607. 35716692.
-
Comment Randomized Controlled Trial
In adults hospitalized with COVID-19, adding baricitinib vs. dexamethasone to remdesivir did not differ for MV-free survival.
Wolfe CR, Tomashek KM, Patterson TF, et al. Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial. Lancet Respir Med. 2022;10:888-99. 35617986.
-
Comment Meta Analysis
In fibromyalgia, amitriptyline is comparable to FDA-approved drugs for symptoms and acceptability.
Farag HM, Yunusa I, Goswami H, et al. Comparison of amitriptyline and US Food and Drug Administration-approved treatments for fibromyalgia: a systematic review and network meta-analysis. JAMA Netw Open. 2022;5:e2212939. 35587348.